

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 December 2002 (19.12.2002)

PCT

(10) International Publication Number  
WO 02/100396 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/343,  
31/381, 31/404, 31/427, 31/4402, 31/4439, A61P 3/10,  
3/00

(21) International Application Number: PCT/US02/17803

(22) International Filing Date: 6 June 2002 (06.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/296,501 7 June 2001 (07.06.2001) US

(71) Applicant: WYETH [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventors: VITOU, Philippe, John, Robert; 47, rue de Maubeuge, F-75009 Paris (FR). JORDAN, Ronald, Arlie; 51 Carol Lane, Richboro, PA 18954 (US).

(74) Agents: MILOWSKY, Arnold, S. et al.; Wyeth, Patent Law Department, Five Giralda Farms, Madison, NJ 07940-0874 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/100396 A1

(54) Title: COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT

(57) Abstract: This invention provides methods of using a pharmacological combination of one or more PTPase inhibiting agents and one or more thiazolidinedione agents, including pioglitazone or rosiglitazone, for treatment in a mammal of Syndrome X or type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of

## COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT

5 This invention relates to pharmaceutical combinations of a PTPase inhibiting compound and a thiazolidinedione agent. Particularly, this invention concerns methods of treating or inhibiting Syndrome X or type II diabetes and related conditions in a mammal utilizing combinations of these two classes of pharmacological agents.

### BACKGROUND OF THE INVENTION

10

The prevalence of insulin resistance in glucose intolerant subjects has long been recognized. Reaven et al (*American Journal of Medicine* 1976, 60, 80) used a continuous infusion of glucose and insulin (insulin/glucose clamp technique) and oral glucose tolerance tests to demonstrate that insulin resistance existed in a diverse group of nonobese, nonketotic subjects. These subjects ranged from borderline glucose tolerant to overt, fasting hyperglycemia. The diabetic groups in these studies included both insulin dependent (IDDM) and noninsulin dependent (NIDDM) subjects.

15

Coincident with sustained insulin resistance is the more easily determined hyperinsulinemia, which can be measured by accurate determination of circulating plasma insulin concentration in the plasma of subjects. Hyperinsulinemia can be present as a result of insulin resistance, such as is in obese and/or diabetic (NIDDM) subjects and/or glucose intolerant subjects, or in IDDM subjects, as a consequence of over injection of insulin compared with normal physiological release of the hormone by the endocrine pancreas.

20

25

The association of hyperinsulinemia with obesity and with ischemic diseases of the large blood vessels (e.g. atherosclerosis) has been well established by numerous experimental, clinical and epidemiological studies (summarized by Stout, *Metabolism* 1985, 34, 7, and in more detail by Pyorala et al, *Diabetes/Metabolism Reviews* 1987, 3, 463). Statistically significant plasma insulin elevations at 1 and 2 hours after oral glucose load correlates with an increased risk of coronary heart disease.

30

Since most of these studies actually excluded diabetic subjects, data relating the risk of atherosclerotic diseases to the diabetic condition are not as numerous, but point in the same direction as for nondiabetic subjects (Pyorala et al). However, the incidence of atherosclerotic diseases in morbidity and mortality statistics in the diabetic population exceeds that of the nondiabetic population (Pyorala et al; Jarrett *Diabetes/Metabolism Reviews* 1989,5, 547; Harris et al, Mortality from diabetes, in *Diabetes in America* 1985).

The independent risk factors obesity and hypertension for atherosclerotic diseases are also associated with insulin resistance. Using a combination of insulin/glucose clamps, tracer glucose infusion and indirect calorimetry, it has been demonstrated that the insulin resistance of essential hypertension is located in peripheral tissues (principally muscle) and correlates directly with the severity of hypertension (DeFronzo and Ferrannini, *Diabetes Care* 1991, 14, 173). In hypertension of the obese, insulin resistance generates hyperinsulinemia, which is recruited as a mechanism to limit further weight gain via thermogenesis, but insulin also increases renal sodium reabsorption and stimulates the sympathetic nervous system in kidneys, heart, and vasculature, creating hypertension.

It is now appreciated that insulin resistance is usually the result of a defect in the insulin receptor signaling system, at a site post binding of insulin to the receptor. Accumulated scientific evidence demonstrating insulin resistance in the major tissues which respond to insulin (muscle, liver, adipose), strongly suggests that a defect in insulin signal transduction resides at an early step in this cascade, specifically at the insulin receptor kinase activity, which appears to be diminished (reviewed by Haring, *Diabetologia* 1991, 34, 848).

Protein-tyrosine phosphatases (PTPases) play an important role in the regulation of phosphorylation of proteins. The interaction of insulin with its receptor leads to phosphorylation of certain tyrosine molecules within the receptor protein, thus activating the receptor kinase. PTPases dephosphorylate the activated insulin receptor, attenuating the tyrosine kinase activity. PTPases can also modulate post-receptor signaling by catalyzing the dephosphorylation of cellular substrates of the insulin receptor kinase. The enzymes that appear most likely to closely associate with

the insulin receptor and therefore, most likely to regulate the insulin receptor kinase activity, include PTP1B, LAR, PTP $\alpha$  and SH-PTP2 (B. J. Goldstein, *J. Cellular Biochemistry* 1992, 48, 33; B. J. Goldstein, *Receptor* 1993, 3, 1-15.; F. Ahmad and B. J. Goldstein *Biochim. Biophys Acta* 1995, 1248, 57-69).

5

McGuire et al. (*Diabetes* 1991, 40, 939), demonstrated that nondiabetic glucose intolerant subjects possessed significantly elevated levels of PTPase activity in muscle tissue vs. normal subjects, and that insulin infusion failed to suppress PTPase activity as it did in insulin sensitive subjects.

10

Meyerovitch et al (*J. Clinical Invest.* 1989, 84, 976) observed significantly increased PTPase activity in the livers of two rodent models of IDDM, the genetically diabetic BB rat, and the STZ-induced diabetic rat. Sredy et al (*Metabolism*, 44, 1074, 1995) observed similar increased PTPase activity in the livers of obese, diabetic ob/ob mice, a genetic rodent model of NIDDM.

15

The compounds of us in the methods of this invention have been shown to inhibit PTPases derived from rat liver microsomes and human-derived recombinant PTPase-1B (hPTP-1B) *in vitro*. Their synthesis and use in treatments of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels is taught in published PCT Application WO 99/61435 (Wrobel et al.).

20

### DESCRIPTION OF THE INVENTION


25

This invention provides methods of using a pharmacological combination of one or more PTPase inhibiting agents and one or more thiazolidinedione agents for treatment, inhibition or maintenance of Syndrome X or type II diabetes in a mammal in need of such treatment. Also provided are a method of using these agents to treat or inhibit metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal in need thereof. Further included in this invention is a method of modulating blood glucose levels in a mammal in need thereof.

30

Each of these methods comprises administering to a mammal in need thereof pharmaceutically effective amounts of:


- a) a thiazolidinedione agent, such as selected from the group of pioglitazone and rosiglitazone, or a pharmaceutically acceptable salt form of these agents; and
- b) a PTPase inhibiting compound of formula I:



(I)

wherein:

Ar is



10

A is hydrogen, halogen, or OH;

B and D are each, independently, hydrogen, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl of 6-12 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, hydroxyaralkyl of 6-12 carbon atoms, cycloalkyl of 3-8 carbon atoms, nitro, amino,  $-NR^1R^{1a}$ ,  $-NR^1COR^{1a}$ ,  $-NR^1CO_2R^{1a}$ , cycloalkylamino of 3-8 carbon atoms, morpholino, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl,  $-COR^{1b}$  or OR;

15

R is hydrogen, alkyl of 1-6 carbon atoms,  $-COR^1$ ,  $-(CH_2)_nCO_2R^1$ ,  $-CH(R^{1a})CO_2R^1$ ,  $-SO_2R^1$ ,  $-(CH_2)_mCH(OH)CO_2R^1$ ,  $-(CH_2)_mCOCO_2R^1$ ,  $-(CH_2)_mCH=CHCO_2R^1$ , or  $-(CH_2)_mO(CH_2)_oCO_2R^1$ ;

20

$R^1$  is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl, or  $CH_2CO_2R^{1'}$ ;

$R^{1'}$  is hydrogen or alkyl of 1-6 carbon atoms

E is S, SO, SO<sub>2</sub>, O, or NR<sup>1c</sup>;

X is hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, CN, aryl, aralkyl of 6-12 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, hydroxyaralkyl of 6-12 carbon atoms, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aryloxy; arylalkoxy, nitro, amino, NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>COR<sup>2a</sup>, cycloalkylamino of 3-8 carbon atoms, morpholino, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylaminoethylsulfanyl, -OCH<sub>2</sub>CO<sub>2</sub>R<sup>2b</sup> or -COR<sup>2c</sup>;

Y is hydrogen, halogen, alkyl of 1-6 carbon atoms, aryl, aralkyl of 6-12 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, hydroxyaralkyl of 6-12 carbon atoms, -OR<sup>3</sup>, SR<sup>3</sup>, NR<sup>3</sup>R<sup>3a</sup>, -COR<sup>3b</sup>, morpholine or piperidine;

R<sup>1a</sup>, R<sup>1c</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup>, R<sup>3a</sup> are each, independently, hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, or aryl;

R<sup>1b</sup> is alkyl of 1-6 carbon atoms or aryl;




R<sup>2b</sup> is hydrogen, alkyl of 1-6 carbon atoms;

R<sup>2c</sup> and R<sup>3b</sup> are each, independently, alkyl of 1-6 carbon atoms, aryl, or aralkyl of 6-12 carbon atoms;

C is hydrogen, halogen or OR<sup>4</sup>;

R<sup>4</sup> is hydrogen, alkyl of 1-6 carbon atoms, -CH(R<sup>5</sup>)W, -C(CH<sub>3</sub>)<sub>2</sub>CO<sub>2</sub>R<sup>6</sup>, 5-thiazolidine-2,4-dione, -CH(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>R<sup>6</sup>, -COR<sup>6</sup>, -PO<sub>3</sub>(R<sup>6</sup>)<sub>2</sub>, -SO<sub>2</sub>R<sup>6</sup>, -(CH<sub>2</sub>)<sub>p</sub>CH(OH)CO<sub>2</sub>R<sup>6</sup>, -(CH<sub>2</sub>)<sub>p</sub>COCO<sub>2</sub>R<sup>6</sup>, -(CH<sub>2</sub>)<sub>p</sub>CH=CHCO<sub>2</sub>R<sup>6</sup>, or -(CH<sub>2</sub>)<sub>p</sub>O(CH<sub>2</sub>)<sub>q</sub>CO<sub>2</sub>R<sup>6</sup>;

R<sup>5</sup> is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl, -CH<sub>2</sub>(1H-imidazol-4-yl), -CH<sub>2</sub>(3-1H-indolyl), -CH<sub>2</sub>CH<sub>2</sub>(1,3-dioxo-1,3-dihydro-isoindol-2-yl), -CH<sub>2</sub>CH<sub>2</sub>(1-oxo-1,3-dihydro-isoindol-2-yl), -CH<sub>2</sub>(3-pyridyl), -CH<sub>2</sub>CO<sub>2</sub>H, or -(CH<sub>2</sub>)<sub>n</sub>G;

G is NR<sup>6a</sup>R<sup>7a</sup>, NR<sup>6a</sup>COR<sup>7a</sup>, , , or  ;

W is  $\text{CO}_2\text{R}^6$ ,  $\text{CONH}_2$ ,  $\text{CONHOH}$ ,  $\text{CN}$ ,  $\text{CONH}(\text{CH}_2)_2\text{CN}$ , 5-tetrazole,  $-\text{PO}_3(\text{R}^6)_2$ ,  
- $\text{CH}_2\text{OH}$ ,  $-\text{CONR}^{6b}\text{CHR}^{7b}$ ,  $-\text{CH}_2\text{NR}^{6b}\text{CHR}^{7b}\text{CO}_2\text{R}^6$ ,  $-\text{CH}_2\text{OCHR}^{7b}\text{CO}_2\text{R}^6$   
- $\text{CH}_2\text{Br}$ , or  $-\text{CONR}^{6b}\text{CHR}^{7b}\text{CO}_2\text{R}^6$ ;

5  $\text{R}^6$ ,  $\text{R}^{6a}$ ,  $\text{R}^7$ ,  $\text{R}^{7a}$  are each, independently, is hydrogen, alkyl of 1-6 carbon atoms, or  
aryl;

$\text{R}^{6b}$  is hydrogen or  $-\text{COR}^{6c}$ ;

$\text{R}^{6c}$  is alkyl of 1-6 carbon atoms or aryl;

$\text{R}^{7b}$  is hydrogen, alkyl of 1-6 carbon atoms, or hydroxyalkyl of 1-6 carbon atoms;

10  $\text{Z}^1$  and  $\text{Z}^2$  are each, independently, hydrogen, halogen,  $\text{CN}$ , alkyl of 1-6 carbon atoms,  
aryl, aralkyl of 6-12 carbon atoms, cycloalkyl of 3-8 carbon atoms, nitro, amino,  
- $\text{NR}^1\text{R}^{1a}$ ,  $-\text{NR}^1\text{COR}^{1a}$ , cycloalkylamino of 3-8 carbon atoms, morpholino, or  
 $\text{OR}^8$ , or  $\text{Z}^1$  and  $\text{Z}^2$  may be taken together as a diene unit having the formula  
- $\text{CH}=\text{CR}^9-\text{CR}^{10}=\text{CR}^{11}-$ ;

$\text{R}^8$  is hydrogen, alkyl of 1-6 carbon atoms, or aryl;

15  $\text{R}^9$ ,  $\text{R}^{10}$ , and  $\text{R}^{11}$  are each, independently, hydrogen, alkyl of 1-6 carbon atoms, aryl,  
halogen, hydroxy, or alkoxy of 1-6 carbon atoms

$m$  is 1 to 4

$n$  is 1 or 2;

$p$  is 1 to 4;

20  $q$  is 1 to 4;

or a pharmaceutically acceptable salt or ester form thereof.

The synthesis and PTPase inhibiting and anti-diabetic activities of the  
compounds described herein are demonstrated in published PCT Application WO  
25 99/61435 (Wrobel et al.), published December 2, 1999, the contents of which are  
incorporated herein by reference.

Pharmaceutically acceptable salts of these compounds can be formed from  
organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric,  
30 succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric,  
hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, naphthalenesulfonic,

benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids when a compound of this invention contains a basic moiety, such as when R<sup>5</sup> is CH<sub>2</sub>(3-pyridyl), or Y is morpholine or contains similar basic moieties. Salts may also be formed from organic and inorganic bases, preferably alkali metal salts, for example,  
5 sodium, lithium, or potassium, when a compound of this invention contains a carboxylate or phenolic moiety.


Alkyl includes both straight chain as well as branched moieties. Halogen means bromine, chlorine, fluorine, and iodine. It is preferred that aryl as a group or  
10 part of a group, e.g. aralkyl, arylalkoxy or aryloxy is a phenyl or naphthyl; with phenyl being most preferred. The aryl moiety or portion may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, halogen, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms, and dialkylamino in which each of the  
15 alkyl groups is of 1-6 carbon atoms, nitro, cyano, -CO<sub>2</sub>H, alkylcarbonyloxy of 2-7 carbon atoms, and alkylcarbonyl of 2-7 carbon atoms. Aralkyl may for example be benzyl.

The PTPase inhibiting compounds used in the methods of this invention may  
20 contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry in Formula I, the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other  
25 mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.

The PTPase inhibiting compounds of this invention may be atropisomers by virtue of possible restricted or slow rotation about the aryl-tricyclic or aryl-bicyclic single bond. This restricted rotation creates additional chirality and leads to  
30 enantiomeric forms. If there is an additional chiral center in the molecule, diastereomers exist and can be seen in the NMR and via other analytical techniques. While shown without respect to atropisomer stereochemistry in Formula I, the present invention includes such atropisomers (enantiomers and diastereomers; as well as the

racemic, resolved, pure diastereomers and mixtures of diastereomers) and pharmaceutically acceptable salts thereof.

Preferred PTPase inhibiting compounds of use in this invention include those  
5 having the structure:



(I)

wherein:

A is hydrogen or halogen;

B and D are each, independently, hydrogen, halogen, CN, alkyl of 1-6 carbon atoms,  
10 aryl, aralkyl of 6-12 carbon atoms, branched alkyl, cycloalkyl of 3-8 carbon atoms, nitro or OR;

R is hydrogen or alkyl of 1-6 carbon atoms;

E is S, or O;

X is hydrogen, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon  
15 atoms, alkoxy of 1-6 carbon atoms, aryloxy; arylalkoxy, nitro, amino, NR<sup>2</sup>R<sup>2a</sup>, NR<sup>2</sup>COR<sup>2a</sup>, cycloalkylamino, morpholino, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylaminoethylsulfanyl;

R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup>, and R<sup>3a</sup> are each, independently, hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, or aryl;

20 Y is hydrogen, halogen, OR<sup>3</sup>, SR<sup>3</sup>, NR<sup>3</sup>R<sup>3a</sup> or morpholine;

C is hydrogen, halogen, or OR<sup>4</sup>;

R<sup>4</sup> is hydrogen, alkyl of 1-6 carbon atoms, -CH(R<sup>5</sup>)W, -C(CH<sub>3</sub>)<sub>2</sub>CO<sub>2</sub>R<sup>6</sup>, 5-thiazolidine-2,4-dione, -CH(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>R<sup>6</sup>, -COR<sup>6</sup>, -PO<sub>3</sub>(R<sup>6</sup>)<sub>2</sub>, -SO<sub>2</sub>R<sup>6</sup>,

$-(CH_2)_pCH(OH)CO_2R^6$ ,  $-(CH_2)_pCOCO_2R^6$ ,  $-(CH_2)_pCH=CHCO_2R^6$ , or  
 $-(CH_2)_pO(CH_2)_qCO_2R^6$ ;

$R^5$  is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl,  
 $-CH_2(1H\text{-imidazol-4-yl})$ ,  $-CH_2(3\text{-}1H\text{-indolyl})$ ,  $-CH_2CH_2(1,3\text{-dioxo-}1,3\text{-dihydro-}$   
 5  $\text{isoindol-2-yl})$ ,  $-CH_2CH_2(1\text{-oxo-}1,3\text{-dihydro-isoindol-2-yl})$ , or  $-CH_2(3\text{-pyridyl})$ ;

W is  $CO_2R^6$ ,  $-CONH_2$ ,  $-CONHOH$ , or 5-tetrazole, or  $-CONR^{6b}CHR^{7b}CO_2R^6$ ;

$R^6$ ,  $R^{6a}$ ,  $R^{6b}$ ,  $R^7$ ,  $R^{7a}$ , and  $R^{7b}$  are each, independently, hydrogen, alkyl of 1-6  
 carbon atoms, or aryl;

$Z^1$  and  $Z^2$  are each, independently, hydrogen, halogen, CN, alkyl of 1-6 carbon atoms,  
 10 aryl, aralkyl of 6-12 carbon atoms, cycloalkyl of 3-8 carbon atoms, nitro, amino,  
 $-NR^1R^{1a}$ ,  $-NR^1COR^{1a}$ , cycloalkylamino of 3-8 carbon atoms, morpholino, or  
 $OR^8$ , or  $Z^1$  and  $Z^2$  may be taken together as a diene unit having the formula -  
 $CH=CR^9-CR^{10}=CH-$ ;


$R^9$  and  $R^{10}$  are independently, hydrogen, or alkyl of 1-6 carbon atoms;

15 p is 1 to 4;

q is 1 to 4;

or a pharmaceutically acceptable salt or ester form thereof.

20 More preferred PTPase inhibiting compounds for use in the methods of this  
 invention include those of the structure:



(I)

wherein:

A is hydrogen;

B and D are each, independently, halogen, alkyl of 1-6 carbon atoms, aryl, aralkyl of 6-12 carbon atoms, or cycloalkyl of 3-8 carbon atoms;

E is S or O;

5 X is hydrogen, halogen, alkyl of 1-6 carbon atoms, perfluoroalkyl of 1-6 carbon atoms, CN, alkoxy of 1-6 carbon atoms, aryloxy, arylalkoxy of 6-12 carbon atoms, arylsulfanyl;

Y is hydrogen or  $-NR^1R^2$ , or morpholine;

$R^1$  and  $R^2$  are each, independently, hydrogen or alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, or aryl;

10 C is  $OR^4$ ;

$R^4$  is hydrogen, alkyl of 1-6 carbon atoms,  $-CH(R^5)W$ , or 5-thiazolidine-2,4-dione;

$R^5$  is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl,  $-CH_2(3-1H-indolyl)$ ,  $-CH_2CH_2(1,3-dioxo-1,3-dihydro-isoindol-2-yl)$ , or  $-CH_2CH_2(1-oxo-1,3-dihydro-isoindol-2-yl)$ ;

15 W is  $-CO_2R^6$ ,  $-CONH_2$ ,  $-CONHOH$ , 5-tetrazole,  $-PO_3(R^6)_2$ , or  $-CONR^6CHR^6CO_2R^6$

$R^6$  is hydrogen or alkyl of 1-6 carbon atoms;

$Z^1$  and  $Z^2$  are taken together as a diene unit having the formula  $-CH=CH-H=CH-$ ; or a pharmaceutically acceptable salt thereof.

20 Even more preferred PTPase inhibiting compounds of this invention include:

(R)-2-[2,6-dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;

25 (R)-2-[2-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-ethyl-phenoxy]-3-phenyl-propionic acid;

(R)-2-[4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2, 6-dimethyl-phenoxy]-3-phenyl-propionic acid;

30

(R)-2-[4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-fluoro-phenoxy]-3-phenyl-propionic acid;

[4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2, 6-diisopropyl-phenoxy]-acetic acid;

5 (R)-2-[2-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-sec-butyl-phenoxy]-3-phenyl-propionic acid;

(R)-2-[2-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-isopropyl-phenoxy]-3-phenyl-propionic acid;

10 (R)-2-[2-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-cyclopentyl-phenoxy]-3-phenyl-propionic acid

(R)-2-[4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-isopropyl-phenoxy]-3-phenyl-propionic acid;

15 (R)-2-[4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-cyclopentyl-phenoxy]-3-phenyl-propionic acid;

20 (R)-2-[2,6-dibromo-4-(2,3-dimethyl-9-phenylsulfanyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;

(R)-2-[2,6-dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-4-phenyl-butyric acid;


25 (S)-2-[2,6-dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-4-phenyl-butyric acid;

2-[2,6-dibromo-4-(9-bromo-3-methyl-2-morpholin-4-yl)methyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;

30 (R)-2-[2,6-dibromo-4-(2,3-dimethyl-9-phenylsulfanyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-propionic acid;

- [2-bromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-nitro-phenoxy]-3-phenyl-propionic acid;
- 2, 6-dibromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenol;
- 5 2-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-nitro-phenol;
- (R)-2-[2,6-dibromo-4-(9-bromo-2-diethylaminomethyl-3-methyl-naphtho[2,3-b]-thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;
- 10 (R)-2-[2, 6-dibromo-4-(2, 3-dimethyl-naphtho[2,3-b]furan-4-yl)-phenoxy]-3-phenyl-propionic acid;
- (2R)-2-[4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diisopropyl-phenoxy]-3-phenyl-propionic acid,
- 15 (R)-2-[4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionic acid,
- 20 {(2R)-2-[4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionylamino}-acetic acid;
- {(2R)-2-[4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionylamino}-acetic acid
- 25 or pharmaceutically acceptable salts thereof.

Among the most preferred PTPase inhibiting compounds for use in the present inventions is (2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid, having the structure:



or its pharmaceutically acceptable salt or ester forms.

Among the more preferred thiazolidinedione agents of this invention are the  
5 non-limiting group of pioglitazone or rosiglitazone, or a pharmaceutically acceptable  
salt form of these agents. Each of these agents may be produced by methods known  
in the art. These agents may also be administered at the pharmaceutically or  
therapeutically effective dosages or amounts known in the art for these compounds,  
such as those described in the Physician's Desk Reference 2001, 55 Edition,  
10 Copyright 2001, published by Medical Economics Company, Inc., the relevant portions  
describing each of these products being incorporated herein by reference.

Pioglitazone is available in the form of 15 mg, 30 mg and 45 mg ACTOS®  
brand pioglitazone hydrochloride tablets from Swiss Bioceutical International, Ltd.  
15 Pioglitazone and its pharmaceutically acceptable salt forms may be administered in  
humans at an initial daily dose of from about 15 mg or 30 mg and increased, as  
needed, to a maximum daily dose of about 45 mg.

Rosiglitazone is available in the form of 2 mg, 4 mg and 8 mg AVANDIA®  
20 rosiglitazone maleate tablets from GlaxoSmithKline. Rosiglitazone may be  
administered in humans at an initial daily dose of about 4 mg in a single or divided  
doses and increased, as needed, up to a maximum daily dose of 8 mg.

This invention provides methods for treating, preventing, inhibiting or  
25 ameliorating the basis or symptoms of Syndrome X or type II diabetes in a mammal,  
preferably in a human, in need of such help. This invention also comprises a method

of treating, inhibiting, preventing or reducing the symptoms, physiological basis or causative elements of metabolic disorders mediated by insulin resistance or hyperglycemia in such a mammal in need thereof, particularly including those typically associated with obesity or glucose intolerance. Also provided by this invention is a  
5 method for modulating blood glucose levels in such a mammal in need thereof. Modulating blood glucose levels as used herein is understood to indicate maintaining glucose levels within clinically normal ranges or lowering elevated blood glucose levels to a more clinically desirable level or range. The combinations of this invention may also be used in methods of increasing insulin sensitivity in a mammal in need of such  
10 action, particularly including a mammal experiencing or subject to Syndrome X or type II diabetes.

The methods herein each comprise administering to a mammal in need thereof a pharmaceutically or therapeutically effective amount of a PTPase inhibitor of this  
15 invention, as described herein, and a pharmaceutically or therapeutically effective amount of a thiazolidinedione agent. As used herein a pharmaceutically or therapeutically effective amount is understood to be at least a minimal amount which provides a medical improvement in the symptoms of the specific malady or disorder experienced by the mammal in question. Preferably, the recipient will experience a  
20 reduction, inhibition or removal of the biological basis for the malady in question.

Another aspect of this invention is a pharmaceutical composition comprising a pharmaceutically amount of a PTPase inhibiting compound of this invention, a pharmaceutically effective amount of a thiazolidinedione agent, and one or more  
25 pharmaceutically acceptable carriers or excipients.

In another aspect, the invention relates to the use of a thiazolidinone agent and a PTPase inhibitor compound as defined in Claim 1 to 11 in the preparation of a medicament for the treatment of Syndrome X or type II diabetes in a mammal.  
30

In another aspect, the invention relates to a product comprising a thiazolidinone agent and a PTPase inhibitor compound as defined in Claim 1 to 11 as a combined preparation for simultaneous, sequential or separate use in the treatment of Syndrome X or type II diabetes in a mammal.

Effective administration of the PTPase inhibiting compounds of this invention may be given at a daily dosage of from about 1 mg/kg to about 250 mg/kg, and may be given in a single dose or in two or more divided doses. Such doses may be administered in any manner useful in directing the active compounds herein to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally. For the purposes of this disclosure, transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).

Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc. Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar. Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s). Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water soluble suppository bases, such as polyethylene glycols of various molecular weights, may also be used.

It is understood that the dosage, regimen and mode of administration of these compounds will vary according to the malady and the individual being treated and will be subject to the judgment of the medical practitioner involved. It is preferred that the administration of one or more of the compounds herein begin at a low dose and be  
5 increased until the desired effects are achieved. It is also preferred that the recipient also utilize art recognized lifestyle patterns for reducing the incidence of the maladies described herein. These include maintenance of an appropriate diet and exercise regimen, as recommended by a medical practitioner familiar with the physical condition of the recipient.

10

The following are representative PTPase inhibiting compound examples useful in the methods of this invention. Their synthesis is described in published PCT Application WO 99/61435, published December 2, 1999, the contents of which are incorporated herein by reference.

15

**Example 1** - 2,3- Dimethyl-thiophene;

**Example 2** - 4, 5-Dimethylthiophene-2-yl-(phenyl)-methanol;

**Example 3** - 2-Benzyl-4, 5 dimethylthiophene;

**Example 4** - (2-Benzyl-4, 5-dimethyl-thiophen-3-yl)-(4-methoxy-phenyl)-methanone;

20  

**Example 5** - 4-(2, 3-Dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenol;

**Example 6** - Acetic Acid 4-(2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenyl ester;

**Example 7** - Acetic Acid 4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenyl ester;

**Example 8** - 4-(9-Bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenol;

25  

**Example 9** - 2, 6-Dibromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenol;

**Example 10** - Methanesulfonic acid 4-(2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenyl ester;

30  

**Example 11** - Methanesulfonic acid 4-(9-iodo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenyl ester;

**Example 12** - 4-(2,3-Dimethyl-9-phenylsulfanyl-naphtho[2,3-b]thiophen-4-yl)-phenol;

**Example 13** - 2,6-Dibromo-4-(2,3-dimethyl-9-phenylsulfanyl-naphtho[2,3-b]thiophen-4-yl)-phenol;

- Example 14** - Acetic acid 4-(9-bromo-2-chloromethyl-3-methyl-naphtho[2,3-b]-thiophen-4-yl)-phenyl ester;
- Example 15** - 4-(9-Bromo-3-methyl-2-morpholin-4-yl)methyl-naphtho[2,3-b]thiophen-4-yl)-phenol;
- 5 **Example 16** - 4-(9-Bromo-2-diethylaminomethyl-3-methyl-naphtho[2,3-b]thiophen-4-yl)-acetate;
- Example 17** - 4-(9-Bromo-2-diethylaminomethyl-3-methyl-naphtho[2,3-b]thiophen-4-yl)-phenol;
- Example 18** - 2,6-Dibromo-4-(9-bromo-2-diethylaminomethyl-3-methyl-naphtho[2,3-b]-thiophen-4-yl)-phenol;
- 10 **Example 19** - 2,6-Dibromo-4-(9-bromo-3-methyl-2-morpholin-4-yl)methyl-naphtho[2,3-b]thiophen-4-yl)-phenol;
- Example 20** - 4-(9-Bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-nitro-phenol;
- Example 21** - 2-Bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-nitro-phenol;
- 15 **Example 22** - 2-Amino-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenol;
- Example 23** - 2-Amino-6-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenol;
- Example 24** - [2-Bromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-nitro-phenoxy]-acetic acid;
- 20 **Example 25** - (S)-2-Hydroxy-3-phenylpropionic acid, methyl ester;
- Example 26** - (S)-2-[4-Nitrobenzoyl]-4-phenylbutyric acid, ethyl ester;
- Example 27** - (S)-2-Hydroxy-4-phenylbutyric Acid, ethyl ester;
- Example 28** - (R)-2-[2,6-Dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]3-phenyl-propionic acid methyl ester;
- 25 **Example 29** - (R)-2-[2,6-Dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]3-phenyl-propionic acid;
- Example 30** - (R)-2-[2,6-Dibromo-4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thien-4-yl)-phenoxy]-propanoic acid;
- 30 **Example 31** - (S)-2-[2,6-Dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-4-phenyl-butyric acid;
- Example 32** - (R)-2-[2,6-Dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-4-phenyl-butyric acid;

- Example 33** - (R)-2-[2,6-dibromo-4-(2,3-dimethyl-9-phenylsulfanyl-naphtho[2,3-b]-thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;
- Example 34** - (R)-2-[2,6-Dibromo-4-(2,3-dimethyl-9-phenylsulfanyl-naphtho[2,3-b]-thiophen-4-yl)-phenoxy]-propionic acid;
- 5 **Example 35** - 2-[2,6-Dibromo-4-(9-bromo-3-methyl-2-morpholin-4-ylmethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;
- Example 36** - 2-[2,6-Dibromo-4-(9-bromo-3-methyl-2-morpholin-4-ylmethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-propionic acid;
- Example 37** - (R)-2-[2,6-Dibromo-4-(9-bromo-2-diethylaminomethyl-3-methyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;
- 10 **Example 38** - [2-Bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-nitro-phenoxy]-3-phenyl-propionic acid;
- Example 39** - 2-Bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-isopropyl-phenol;
- 15 **Example 40** - (R)-2-[2-Bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-isopropyl-phenoxy]-3-phenyl-propionic acid;
- Example 41** - (R)-2-[4-(2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-isopropyl-phenoxy]-3-phenyl-propionic acid;
- Example 42** - (R)-2-[2-Bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-sec-butyl-phenoxy]-3-phenyl-propionic acid;
- 20 **Example 43** - (R)-2-[2-Bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-ethyl-phenoxy]-3-phenyl-propionic acid;
- Example 44** - (R)-2-[4-(9-Bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-isopropyl-phenoxy]-3-phenyl-propionic acid;
- 25 **Example 45** - (R)-2-[2-Cyclopentyl-4-(2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;
- Example 46** - (R)-2-[4-(2,3-Dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid;
- Example 47** - (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-cyclopentyl-phenoxy]-3-phenyl-propionic acid;
- 30 **Example 48** - (R)-2-[2-Bromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-cyclopentyl-phenoxy]-3-phenyl-propionic acid;
- Example 49** - (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid;

- Example 50** - (R)-2-[4-(2, 3-Dimethyl-naphtho[2,3-b]thiophen-4-yl)-2, 6-diisopropyl-phenoxy]-3-phenyl-propionic acid;
- Example 51** - (R)-2-[4-(2,3-Dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-fluoro-phenoxy]-3-phenyl-propionic acid;
- 5 **Example 52** - (R)-2-[4-(9-Bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-fluoro-phenoxy]-3-phenyl-propionic acid;
- Example 53** - [4-(9-Bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2, 6-diisopropyl-phenoxy]-acetic acid;
- Example 54** - (2R)-2-[2,6-Dibromo-4-(2,3-dimethyl-naphtho[2,3-b]furan-4-yl)-phenoxy]-  
10 3-phenyl-propionic acid;
- Example 55** - (2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diisopropyl-phenoxy]-3-phenyl-propionic acid;
- Example 56** - [3-Bromo-5-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-hydroxy-phenyl]-carbamic acid tert-butyl ester;
- 15 **Example 57** - 9-Bromo-4-(3-bromo-methoxy-5-nitro-phenyl)-2, 3-dimethyl-naphtho[2,3-b]thiophene;
- Example 58** - 3-Bromo-5-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-methoxy-phenylamine;
- Example 59** - [3-Bromo-5-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-methoxy-phenylamino]-acetic acid methyl ester;
- 20 **Example 60** - [3-Bromo-5-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-methoxy-phenylamino]-acetic acid;
- Example 61** - (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionic acid;
- 25 **Example 62** - {(2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionylamino}-acetic acid;
- Example 63** - {(2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionylamino}-acetic acid;
- Example 64** - (2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-  
30 3-phenyl-propionic acid ;
- Example 65** - (2S)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid;
- Example 66** - (2R)-2-[4-(9-Bromo-2,3-dimethyl-1-oxo-1H-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid;

- Example 67** - (R)-2-[4-(2,3-Dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionic acid;
- Example 68** - {(2R)-2-[4-(2,3-Dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionylamino}-acetic acid;
- 5 **Example 69** - 4-(2,3-Dimethyl-naphtho[2,3-b]furan-4-yl)-2,6-diethyl-phenol;
- Example 70** - (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]furan-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionic acid;
- Example 71** - (R)-2-[2-Cyclopentyl-4-(2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-propionic acid;
- 10 **Example 72** - (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-cyclopentyl-phenoxy]-propionic acid ;
- Example 73** - 4-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-cyclopentyl-phenoxy]-butyric acid;
- Example 74** - 2-Cyclopentyl-4-(2,3-dimethyl-naphtho[2,3-b]furan-4-yl)-phenol;
- 15 **Example 75** - Acetic acid 2-cyclopentyl-4-(2,3-dimethyl-naphtho[2,3-b]furan-4-yl)-phenyl ester;
- Example 76** - (R)-2-[4-(2,3-Dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-ethyl-phenoxy]-3-phenyl-propionic acid ;
- Example 77** - (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-ethyl-phenoxy]-3-phenyl-propionic acid;
- 20 **Example 78** - 2-Bromo-4-(2,3-dimethyl-naphtho[2,3-b]furan-4-yl)-6-ethyl-phenol;
- Example 79** - (R)-2-[2-Bromo-4-(2,3-dimethyl-naphtho[2,3-b]furan-4-yl)-6-ethyl-phenoxy]-3-phenyl-propionic acid ;
- Example 80** - 4-[2-Bromo-4-(2,3-dimethyl-naphtho[2,3-b]furan-4-yl)-6-ethyl-phenoxy]-butyric acid ;
- 25 **Example 81** - 4-[2-Bromo-4-(2,3-dimethyl-naphtho[2,3-b]furan-4-yl)-6-ethyl-phenoxy]-butyramide 0.4 hydrate ;
- Example 82** - 4-(2,3-Dimethyl-naphtho[2,3-b]furan-4-yl)-2-ethyl-phenol ;
- Example 83** - (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-propyl-phenoxy]-3-phenyl-propionic acid ;
- 30 **Example 84** - [9-Bromo-4-(4-methoxy-3,5-dimethylphenyl)-3-methylnaphtho[2,3-b]-thien-2-yl]methyl acetate ;
- Example 85** - 4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thien-4-yl)-2-methyl-phenyl acetate;


**Example 86** - Acetic acid 4-(9-bromo-2-diethylaminomethyl-3-methyl-naphtho[2,3-b]-thiophen-4-yl)-2,6-dimethyl-phenyl ester;

**Example 87** - 2-[4-(9-Bromo-2-diethylaminomethyl-3-methyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid ; and

- 5 **Example 88** - (2R)-2-[4-(9-Bromo-2-diethylaminomethyl-3-methyl-naphtho[2,3-b]-thiophen-4-yl)-2,6-diisopropyl-phenoxy]-3-phenyl-propionic acid;  
or the pharmaceutically acceptable salt or ester forms thereof.


**CLAIMS:**

1. A method of treatment for Syndrome X or type II diabetes in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a thiazolidinedione agent and a pharmaceutically effective amount of a PTPase inhibiting compound of formula I:



wherein

Ar is



10

A is hydrogen, halogen, or OH;

15

B and D are each, independently, hydrogen, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl of 6-12 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, hydroxyaralkyl of 6-12 carbon atoms, cycloalkyl of 3-8 carbon atoms, nitro, amino,  $-NR^1R^{1a}$ ,  $-NR^1COR^{1a}$ ,  $-NR^1CO_2R^{1a}$ , cycloalkylamino of 3-8 carbon atoms, morpholino, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-3-yl,  $-COR^{1b}$  or OR;

20

R is hydrogen, alkyl of 1-6 carbon atoms,  $-COR^1$ ,  $-(CH_2)_nCO_2R^1$ ,  $-CH(R^{1a})CO_2R^1$ ,  $-SO_2R^1$ ,  $-(CH_2)_mCH(OH)CO_2R^1$ ,  $-(CH_2)_mCOCO_2R^1$ ,  $-(CH_2)_mCH=CHCO_2R^1$ , or  $-(CH_2)_mO(CH_2)_oCO_2R^1$ ;

$R^1$  is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl, or  $CH_2CO_2R^{1'}$ ;

$R^{1'}$  is hydrogen or alkyl of 1-6 carbon atoms

E is S, SO,  $SO_2$ , O, or  $NR^{1c}$ ;

X is hydrogen, halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-7 carbon atoms, CN, aryl, aralkyl of 6-12 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, hydroxyaralkyl of 6-12 carbon atoms, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aryloxy; arylalkoxy, nitro, amino, NR<sup>2</sup>R<sup>2a</sup>,  
 5 NR<sup>2</sup>COR<sup>2a</sup>, cycloalkylamino of 3-8 carbon atoms, morpholino, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylaminoethyl-sulfanyl, -OCH<sub>2</sub>CO<sub>2</sub>R<sup>2b</sup> or -COR<sup>2c</sup>;

Y is hydrogen, halogen, alkyl of 1-6 carbon atoms, aryl, aralkyl of 6-12 carbon atoms, hydroxyalkyl of 1-6 carbon atoms, hydroxyaralkyl of 6-12 carbon atoms, -OR<sup>3</sup>,  
 10 SR<sup>3</sup>, NR<sup>3</sup>R<sup>3a</sup>, -COR<sup>3b</sup>, morpholine or piperidine;

R<sup>1a</sup>, R<sup>1c</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup>, R<sup>3a</sup> are each, independently, hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, or aryl;

R<sup>1b</sup> is alkyl of 1-6 carbon atoms or aryl;


R<sup>2b</sup> is hydrogen, alkyl of 1-6 carbon atoms;

15 R<sup>2c</sup> and R<sup>3b</sup> are each, independently, alkyl of 1-6 carbon atoms, aryl, or aralkyl of 6-12 carbon atoms;

C is hydrogen, halogen or OR<sup>4</sup>;

R<sup>4</sup> is hydrogen, alkyl of 1-6 carbon atoms, -CH(R<sup>5</sup>)W, -C(CH<sub>3</sub>)<sub>2</sub>CO<sub>2</sub>R<sup>6</sup>, 5-thiazolidine-2,4-dione, -CH(R<sup>7</sup>)(CH<sub>2</sub>)<sub>m</sub>CO<sub>2</sub>R<sup>6</sup>, -COR<sup>6</sup>, -PO<sub>3</sub>(R<sup>6</sup>)<sub>2</sub>, -SO<sub>2</sub>R<sup>6</sup>,  
 20 -(CH<sub>2</sub>)<sub>p</sub>CH(OH)CO<sub>2</sub>R<sup>6</sup>, -(CH<sub>2</sub>)<sub>p</sub>COCO<sub>2</sub>R<sup>6</sup>, -(CH<sub>2</sub>)<sub>p</sub>CH=CHCO<sub>2</sub>R<sup>6</sup>, or -(CH<sub>2</sub>)<sub>p</sub>O(CH<sub>2</sub>)<sub>q</sub>CO<sub>2</sub>R<sup>6</sup>;

R<sup>5</sup> is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl, -CH<sub>2</sub>(1H-imidazol-4-yl), -CH<sub>2</sub>(3-1H-indolyl), -CH<sub>2</sub>CH<sub>2</sub>(1,3-dioxo-1,3-dihydro-isoindol-2-yl), -CH<sub>2</sub>CH<sub>2</sub>(1-oxo-1,3-dihydro-isoindol-2-yl), -CH<sub>2</sub>(3-pyridyl),  
 25 -CH<sub>2</sub>CO<sub>2</sub>H, or -(CH<sub>2</sub>)<sub>n</sub>G;



W is  $\text{CO}_2\text{R}^6$ ,  $\text{CONH}_2$ ,  $\text{CONHOH}$ ,  $\text{CN}$ ,  $\text{CONH}(\text{CH}_2)_2\text{CN}$ , 5-tetrazole,  $-\text{PO}_3(\text{R}^6)_2$ ,  
 $-\text{CH}_2\text{OH}$ ,  $-\text{CONR}^{6b}\text{CHR}^{7b}$ ,  $-\text{CH}_2\text{NR}^{6b}\text{CHR}^{7b}\text{CO}_2\text{R}^6$ ,  $-\text{CH}_2\text{OCHR}^{7b}\text{CO}_2\text{R}^6$   
 $-\text{CH}_2\text{Br}$ , or  $-\text{CONR}^{6b}\text{CHR}^{7b}\text{CO}_2\text{R}^6$ ;

5  $\text{R}^6$ ,  $\text{R}^{6a}$ ,  $\text{R}^7$ ,  $\text{R}^{7a}$  are each, independently, is hydrogen, alkyl of 1-6 carbon atoms, or aryl;

$\text{R}^{6b}$  is hydrogen or  $-\text{COR}^{6c}$ ;

$\text{R}^{6c}$  is alkyl of 1-6 carbon atoms or aryl;

$\text{R}^{7b}$  is hydrogen, alkyl of 1-6 carbon atoms, or hydroxyalkyl of 1-6 carbon atoms;

10  $\text{Z}^1$  and  $\text{Z}^2$  are each, independently, hydrogen, halogen,  $\text{CN}$ , alkyl of 1-6 carbon atoms, aryl, aralkyl of 6-12 carbon atoms, cycloalkyl of 3-8 carbon atoms, nitro, amino,  $-\text{NR}^{1a}$ ,  $-\text{NR}^1\text{COR}^{1a}$ , cycloalkylamino of 3-8 carbon atoms, morpholino, or  $\text{OR}^8$ , or  $\text{Z}^1$  and  $\text{Z}^2$  may be taken together as a diene unit having the formula  $-\text{CH}=\text{CR}^9-\text{CR}^{10}=\text{CR}^{11}-$ ;

$\text{R}^8$  is hydrogen, alkyl of 1-6 carbon atoms, or aryl;

15  $\text{R}^9$ ,  $\text{R}^{10}$ , and  $\text{R}^{11}$  are each, independently, hydrogen, alkyl of 1-6 carbon atoms, aryl, halogen, hydroxy, or alkoxy of 1-6 carbon atoms

m is 1 to 4


n is 1 or 2;

p is 1 to 4;

20 q is 1 to 4;

or a pharmaceutically acceptable salt thereof.

2. The method according to Claim 1 wherein the PTPase inhibiting compound is as defined in Claim 1, wherein:



25 A is hydrogen or halogen;

B and D are each, independently, hydrogen, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl of 6-12 carbon atoms, branched alkyl, cycloalkyl of 3-8 carbon atoms, nitro or OR;

R is hydrogen or alkyl of 1-6 carbon atoms;

5 E is S, or O;

X is hydrogen, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aryloxy, arylalkoxy, nitro, amino,  $\text{NR}^2\text{R}^{2a}$ ,  $\text{NR}^2\text{COR}^{2a}$ , cycloalkylamino, morpholino, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, or 2-N,N-dimethylaminoethylsulfanyl;

10  $\text{R}^1$ ,  $\text{R}^{1a}$ ,  $\text{R}^2$ ,  $\text{R}^{2a}$ ,  $\text{R}^3$ , and  $\text{R}^{3a}$  are each, independently, hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, or aryl;

Y is hydrogen, halogen,  $\text{OR}^3$ ,  $\text{SR}^3$ ,  $\text{NR}^3\text{R}^{3a}$ , or morpholine;

C is hydrogen, halogen, or  $\text{OR}^4$ ;

15  $\text{R}^4$  is hydrogen, alkyl of 1-6 carbon atoms,  $-\text{CH}(\text{R}^5)\text{W}$ ,  $-\text{C}(\text{CH}_3)_2\text{CO}_2\text{R}^6$ , 5-thiazolidine-2,4-dione,  $-\text{CH}(\text{R}^7)(\text{CH}_2)_m\text{CO}_2\text{R}^6$ ,  $-\text{COR}^6$ ,  $-\text{PO}_3(\text{R}^6)_2$ ,  $-\text{SO}_2\text{R}^6$ ,  $-(\text{CH}_2)_p\text{CH}(\text{OH})\text{CO}_2\text{R}^6$ ,  $-(\text{CH}_2)_p\text{COCO}_2\text{R}^6$ ,  $-(\text{CH}_2)_p\text{CH}=\text{CHCO}_2\text{R}^6$ ,  $-(\text{CH}_2)_p\text{O}(\text{CH}_2)_q\text{CO}_2\text{R}^6$ ;

20  $\text{R}^5$  is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl,  $-\text{CH}_2(1\text{H-imidazol-4-yl})$ ,  $-\text{CH}_2(3\text{-1H-indolyl})$ ,  $-\text{CH}_2\text{CH}_2(1,3\text{-dioxo-1,3-dihydro-isoindol-2-yl})$ ,  $-\text{CH}_2\text{CH}_2(1\text{-oxo-1,3-dihydro-isoindol-2-yl})$ , or  $-\text{CH}_2(3\text{-pyridyl})$ ;

W is  $\text{CO}_2\text{R}^6$ ,  $-\text{CONH}_2$ ,  $-\text{CONHOH}$ , 5-tetrazole, or  $-\text{CONR}^{6b}\text{CHR}^{7b}\text{CO}_2\text{R}^6$ ;

$\text{R}^6$ ,  $\text{R}^{6a}$ ,  $\text{R}^{6b}$ ,  $\text{R}^7$ ,  $\text{R}^{7a}$ , and  $\text{R}^{7b}$  are each, independently, hydrogen, alkyl of 1-6 carbon atoms, or aryl;

25  $\text{Z}^1$  and  $\text{Z}^2$  are each, independently, hydrogen, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl of 6-12 carbon atoms, cycloalkyl of 3-8 carbon atoms, nitro, amino,  $-\text{NR}^1\text{R}^{1a}$ ,  $-\text{NR}^1\text{COR}^{1a}$ , cycloalkylamino of 3-8 carbon atoms, morpholino, or  $\text{OR}^8$ , or  $\text{Z}^1$  and  $\text{Z}^2$  may be taken together as a diene unit having the formula  $-\text{CH}=\text{CR}^9-\text{CR}^{10}=\text{CH}-$ ;

$\text{R}^9$  and  $\text{R}^{10}$  are each, independently, hydrogen, or alkyl of 1-6 carbon atoms;

30 p is 1 to 4;

q is 1 to 4;  
or a pharmaceutically acceptable salt thereof.

3. The method according to Claim 2 wherein the PTPase inhibiting compound is  
5 defined in Claim 2, wherein

A is hydrogen;

B and D are each, independently, halogen, alkyl of 1-6 carbon atoms, aryl, aralkyl of 6-  
12 carbon atoms, or cycloalkyl of 3-8 carbon atoms;

E is S or O;

10 X is hydrogen, halogen, alkyl of 1-6 carbon atoms, perfluoroalkyl of 1-6 carbon atoms,  
CN, alkoxy of 1-6 carbon atoms, aryloxy, arylalkoxy of 6-12 carbon atoms,  
arylsulfanyl;

Y is hydrogen,  $-NR^1R^2$ , or morpholine;

$R^1$  and  $R^2$  are each, independently, hydrogen or alkyl of 1-6 carbon atoms, aralkyl of  
15 6-12 carbon atoms, or aryl;

C is  $OR^4$ ;

$R^4$  is hydrogen, alkyl of 1-6 carbon atoms,  $-CH(R^5)W$ , or 5-thiazolidine-2,4-dione;

$R^5$  is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl,  $-CH_2(3-$   
20  $1H$ -indolyl),  $-CH_2CH_2(1,3$ -dioxo-1,3-dihydro-isoindol-2-yl), or  $-CH_2CH_2(1$ -oxo-  
1,3-dihydro-isoindol-2-yl);

W is  $-CO_2R^6$ ,  $-CONH_2$ ,  $-CONHOH$ , 5-tetrazole,  $-PO_3(R^6)_2$ , or  $-CONR^6CHR^6CO_2R^6$ ;

$R^6$  is hydrogen or alkyl of 1-6 carbon atoms;

$Z^1$  and  $Z^2$  are taken together as a diene unit having the formula  $-CH=CH-H=CH-$ ;  
or a pharmaceutically acceptable salt thereof.

25

4. The method according to Claim 1 wherein the PTPase inhibiting compound is  
(2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-  
phenyl-propionic acid, or a pharmaceutically acceptable salt form thereof.

5. The method according to Claim 1 wherein the PTPase inhibiting compound is selected from the group of:

(R)-2-[2, 6-dibromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;

5 (R)-2-[2-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-ethyl-phenoxy]-3-phenyl-propionic acid;

(R)-2-[4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2, 6-dimethyl-phenoxy]-3-phenyl-propionic acid;

10 (R)-2-[4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-fluoro-phenoxy]-3-phenyl-propionic acid;

[4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2, 6-diisopropyl-phenoxy]-acetic acid; or a pharmaceutically acceptable salt form thereof.

6. The method according to Claim 1 wherein the PTPase inhibiting compound is selected from the group of:

(R)-2-[2-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-sec-butyl-phenoxy]-3-phenyl-propionic acid;

(R)-2-[2-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-isopropyl-phenoxy]-3-phenyl-propionic acid;

20 (R)-2-[2-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-cyclopentyl-phenoxy]-3-phenyl-propionic acid;

(R)-2-[4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-isopropyl-phenoxy]-3-phenyl-propionic acid;

25 (R)-2-[4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-cyclopentyl-phenoxy]-3-phenyl-propionic acid; or a pharmaceutically acceptable salt thereof.

7. The method according to Claim 1 wherein the PTPase inhibiting compound is selected from the group of:

30 (R)-2-[2,6-dibromo-4-(2,3-dimethyl-9-phenylsulfanyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;

(R)-2-[2,6-dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-4-phenyl-butyric acid;

(S)-2-[2,6-dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-4-phenyl-butyric acid;

2-[2,6-dibromo-4-(9-bromo-3-methyl-2-morpholin-4-ylmethyl-naphtho[2,3-b]-thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;

- 5 (R)-2-[2,6-dibromo-4-(2,3-dimethyl-9-phenylsulfanyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-propionic acid; or a pharmaceutically acceptable salt thereof.

8. The method according to Claim 1 wherein the PTPase inhibiting compound is selected from the group of:

- 10 [2-bromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-nitro-phenoxy]-3-phenyl-propionic acid;

2, 6-dibromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenol;

2-bromo-4-(9-bromo-2, 3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-6-nitro-phenol;

- 15 (R)-2-[2,6-dibromo-4-(9-bromo-2-diethylaminomethyl-3-methyl-naphtho[2,3-b]-thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid;

(R)-2-[2,6-dibromo-4-(2,3-dimethyl-naphtho[2,3-b]furan-4-yl)-phenoxy]-3-phenyl-propionic acid; or a pharmaceutically acceptable salt thereof.

9. The method according to Claim 1 wherein the PTPase inhibiting compound is selected from the group of:

(2R)-2-[4-9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diisopropyl-phenoxy]-3-phenyl-propionic acid,

(R)-2-[4-(9-bromo-2-,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionic acid;

- 25 {(2R)-2-[4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionylamino}-acetic acid;

{(2R)-2-[4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionylamino}-acetic acid;

- 30 (2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-3-phenyl-propionic acid; or a pharmaceutically acceptable salt thereof.

10. The method according to Claim 1 wherein the PTPase inhibiting compound is selected from the group of:

(2S)-2-[4-(9-Bromo-2-,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid;

5        {(2R)-2-[4-(2,3-Dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionylamino}-acetic acid;

(R)-2-[4-(9-Bromo-2-,3-dimethyl-naphtho[2,3-b]furan-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionic acid;

10        (R)-2-[2-Cyclopentyl-4-(2-,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]-propionic acid;

(R)-2-[4-(9-Bromo-2-,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-cyclopentyl-phenoxy]-propionic acid; or a pharmaceutically acceptable salt thereof.

11. The method according to Claim 1 wherein the PTPase inhibiting compound is selected from the group of:

(R)-2-[4-(2-,3-Dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-ethyl-phenoxy]-3-phenyl-propionic acid;

2-Bromo-4-(2-,3-dimethyl-naphtho[2,3-b]furan-4-yl)-6-ethyl-phenol;

20        (R)-2-[2-Bromo-4-(2-,3-dimethyl-naphtho[2,3-b]furan-4-yl)-6-ethyl-phenoxy]-3-phenyl-propionic acid;

(R)-2-[4-(9-Bromo-2-,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2-propyl-phenoxy]-3-phenyl-propionic acid;

25        (2R)-2-[4-(9-Bromo-2-diethylaminomethyl-3-methyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diisopropyl-phenoxy]-3-phenyl-propionic acid; or a pharmaceutically acceptable salt thereof.

12. The method according to any one of Claims 1 to 11 wherein the thiazolidinedione agent is selected from group of pioglitazone or rosiglitazone, or a pharmaceutically acceptable salt form thereof.

30

13. A method of treating metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a thiazolidinedione agent and a

pharmaceutically effective amount of a PTPase inhibiting compound, as described in Claim 1, or a pharmaceutically acceptable salt thereof.

14. The method according to Claim 13 wherein the thiazolidinedione agent is selected from group of pioglitazone or rosiglitazone, or a pharmaceutically acceptable salt form thereof.

15. The method according to Claim 13 or 14 wherein the PTPase inhibiting compound is (2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid, or (R)-2-[2,6-Dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]3-phenyl-propionic acid, or (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionic acid, or a pharmaceutically acceptable salt form thereof.

16. A method of modulating blood glucose levels in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a thiazolidinedione agent and a pharmaceutically effective amount of a PTPase inhibiting compound, as described in Claim 1, or a pharmaceutically acceptable salt thereof.

20

17. The method according to Claim 16 wherein the thiazolidinedione agent is selected from group of pioglitazone or rosiglitazone, or a pharmaceutically acceptable salt form thereof.

18. The method according to Claim 16 or 17 wherein the PTPase inhibiting compound is (2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid, or (R)-2-[2,6-Dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-phenoxy]3-phenyl-propionic acid, or (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionic acid, or a pharmaceutically acceptable salt form thereof.

30

19. A pharmaceutical composition comprising a PTPase inhibitor of formula I as defined in Claim 1 to 11 and a thiazolidinone agent together with one or more pharmaceutically acceptable excipients or carriers or both.

5 20. A pharmaceutical composition comprising (2R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-*b*]thiophen-4-yl)-2,6-dimethyl-phenoxy]-3-phenyl-propionic acid, or (R)-2-[2,6-Dibromo-4-(9-bromo-2,3-dimethyl-naphtho[2,3-*b*]thiophen-4-yl)-phenoxy]3-phenyl-propionic acid, or (R)-2-[4-(9-Bromo-2,3-dimethyl-naphtho[2,3-*b*]thiophen-4-yl)-2,6-diethyl-phenoxy]-3-phenyl-propionic acid, or a pharmaceutically acceptable salt form  
10 thereof and a thiazolidinedione agent

21. A pharmaceutical composition according to Claim 19 or 20 wherein the thiazolidinedione agent is selected from pioglitazone or rosiglitazone, or a pharmaceutically acceptable salt form thereof.

15

22. A pharmaceutical composition according to Claim 20 further comprising one or more pharmaceutically acceptable excipients or carriers.

23. Use of a thiazolidinone agent and a PTPase inhibitor compound as defined in  
20 Claim 1 to 11 in the preparation of a medicament for the treatment of Syndrome X or type II diabetes in a mammal.

24. A product comprising a thiazolidinone agent and a PTPase inhibitor compound as defined in Claim 1 to 11 as a combined preparation for simultaneous, sequential or  
25 separate use in the treatment of Syndrome X or type II diabetes in a mammal.

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 02/17803

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/343 A61K31/381 A61K31/404 A61K31/427 A61K31/4402  
A61K31/4439 A61P3/10 A61P3/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ, CHEM ABS Data, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, Y	WO 99 61435 A (AMERICAN HOME PROD) 2 December 1999 (1999-12-02) cited in the application the whole document	1-24
Y	WO 98 57636 A (SMITH STEPHEN ALISTAIR ; SMITHKLINE BEECHAM PLC (GB)) 23 December 1998 (1998-12-23) the whole document	1-24
Y	WO 98 42340 A (CIRD GALDERMA ; FANJOL ANDREA (US); PFAHL MAGNUS (US); LERNHARDT WA) 1 October 1998 (1998-10-01) page 9, line 17 -page 10, line 3	1-24

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

12 September 2002

Date of mailing of the international search report

20/09/2002

Name and mailing address of the ISA

Authorized officer



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/17803

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9961435	A	02-12-1999	AU 3893999 A	13-12-1999
			BG 104918 A	31-08-2001
			BR 9911779 A	06-02-2001
			CA 2330620 A1	02-12-1999
			CN 1308626 T	15-08-2001
			EE 200000653 A	15-04-2002
			EP 1077969 A1	28-02-2001
			HR 20000767 A1	31-10-2001
			JP 2002516321 T	04-06-2002
			NO 20005677 A	05-12-2000
			PL 344081 A1	24-09-2001
			SK 16992000 A3	09-04-2001
			TR 200003333 T2	21-02-2001
			WO 9961435 A1	02-12-1999
WO 9857636	A	23-12-1998	AU 8216398 A	04-01-1999
			BG 104059 A	31-10-2000
			BR 9810444 A	05-09-2000
			CN 1260715 T	19-07-2000
			WO 9857636 A1	23-12-1998
			EP 0999837 A1	17-05-2000
			HU 0003260 A2	28-05-2001
			JP 2002504138 T	05-02-2002
			NO 996265 A	17-12-1999
			PL 343123 A1	30-07-2001
			SK 179399 A3	07-11-2000
			TR 9903095 T2	21-08-2000
			US 2002028768 A1	07-03-2002
			ZA 9805237 A	17-02-2000
WO 9842340	A	01-10-1998	AU 6576398 A	20-10-1998
			BR 9808054 A	07-11-2000
			CN 1256630 T	14-06-2000
			EP 1019049 A1	19-07-2000
			JP 2001521551 T	06-11-2001
			NO 994612 A	24-11-1999
			NZ 337927 A	24-11-2000
			WO 9842340 A1	01-10-1998